Legal & General Group
NKTR icon

Legal & General Group’s Nektar Therapeutics NKTR Stock Holding History

Legal & General Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.2M Buy
16,658
+4,245
+34% +$242K ﹤0.01% 2087
2025
Q4 		$525K Buy
+12,413
New +$695K ﹤0.01% 2413
2025
Q2 		– Sell
-1,027
Closed -$10.5K – 3492
2025
Q1 		$10.5K Hold
1,027
– – ﹤0.01% 3163
2024
Q4 		$14.3K Hold
1,027
– – ﹤0.01% 3154
2024
Q3 		$20K Hold
1,027
– – ﹤0.01% 3047
2024
Q2 		$18.9K Buy
+1,027
New +$21.6K ﹤0.01% 3044
2023
Q2 		– Sell
-27,355
Closed -$288K – 3478
2023
Q1 		$288K Sell
27,355
-8,740
-24% -$264K ﹤0.01% 2466
2022
Q4 		$1.22M Buy
36,095
+946
+3% +$45.8K ﹤0.01% 2088
2022
Q3 		$1.69M Sell
35,149
-6,234
-15% -$371K ﹤0.01% 1950
2022
Q2 		$2.36M Buy
41,383
+95
+0.2% +$5.99K ﹤0.01% 1804
2022
Q1 		$3.34M Buy
41,288
+6,985
+20% +$1.03M ﹤0.01% 1749
2021
Q4 		$6.95M Buy
34,303
+17,581
+105% +$3.81M ﹤0.01% 1400
2021
Q3 		$4.5M Buy
16,722
+2,262
+16% +$544K ﹤0.01% 1603
2021
Q2 		$3.72M Sell
14,460
-3,191
-18% -$883K ﹤0.01% 1692
2021
Q1 		$5.29M Sell
17,651
-2,495
-12% -$777K ﹤0.01% 1528
2020
Q4 		$5.14M Sell
20,146
-1,543
-7% -$399K ﹤0.01% 1444
2020
Q3 		$5.4M Buy
21,689
+1,329
+7% +$418K ﹤0.01% 1297
2020
Q2 		$7.07M Sell
20,360
-1,667
-8% -$520K ﹤0.01% 1143
2020
Q1 		$5.93M Buy
22,027
+1,590
+8% +$492K ﹤0.01% 1084
2019
Q4 		$6.61M Sell
20,437
-25,454
-55% -$7.38M ﹤0.01% 1229
2019
Q3 		$12.5M Buy
45,891
+1,266
+3% +$464K 0.01% 908
2019
Q2 		$23.8M Buy
44,625
+3,292
+8% +$1.65M 0.01% 741
2019
Q1 		$20.8M Buy
41,333
+14,206
+52% +$8.42M 0.01% 740
2018
Q4 		$13.4M Buy
27,127
+3,770
+16% +$2.28M 0.01% 773
2018
Q3 		$21.3M Buy
23,357
+3,059
+15% +$2.61M 0.02% 715
2018
Q2 		$14.8M Buy
20,298
+10,218
+101% +$11.8M 0.01% 782
2018
Q1 		$16.1M Sell
10,080
-10,924
-52% -$14.1M 0.01% 746
2017
Q4 		$18.8M Buy
21,004
+572
+3% +$338K 0.01% 699
2017
Q3 		$7.35M Buy
20,432
+765
+4% +$239K 0.01% 867
2017
Q2 		$5.77M Buy
19,667
+1,780
+10% +$514K ﹤0.01% 914
2017
Q1 		$6.3M Buy
17,887
+276
+2% +$62K 0.01% 845
2016
Q4 		$3.24M Buy
17,611
+9,153
+108% +$1.86M ﹤0.01% 1091
2016
Q3 		$2.17M Buy
8,458
+6,207
+276% +$1.6M ﹤0.01% 1009
2016
Q2 		$472K Buy
2,251
+304
+16% +$68K ﹤0.01% 1358
2016
Q1 		$404K Buy
1,947
+88
+5% +$16.9K ﹤0.01% 1408
2015
Q4 		$473K Hold
1,859
– – ﹤0.01% 1344
2015
Q3 		$300K Buy
1,859
+275
+17% +$48.6K ﹤0.01% 1494
2015
Q2 		$297K Buy
1,584
+86
+6% +$14.8K ﹤0.01% 1543
2015
Q1 		$251K Buy
1,498
+237
+19% +$48.7K ﹤0.01% 1582
2014
Q4 		$296K Sell
1,261
-61
-5% -$13K ﹤0.01% 1388
2014
Q3 		$245K Buy
+1,322
New +$253K ﹤0.01% 1412

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Legal & General Group's NKTR Position: Q1 2026 in Review

Legal & General Group increased its Nektar Therapeutics (NKTR) stake by 34% in Q1 2026, buying an estimated $242K and bringing the position to 16,658 shares worth $1.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2087.

Legal & General Group first reported a position in NKTR in Q3 2014 and has held it in 41 quarters since. The position peaked at $23.8M in Q2 2019. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Legal & General Group held 16,658 shares of Nektar Therapeutics worth $1.2M as of Q1 2026.
  • Legal & General Group bought 4,245 Nektar Therapeutics shares in Q1 2026, an estimated $242K.
  • Nektar Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #2087 holding.
  • Legal & General Group first reported a position in Nektar Therapeutics in Q3 2014 and has held it in 41 quarters since.
  • Legal & General Group's Nektar Therapeutics position peaked at $23.8M in Q2 2019.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.